CONNECT WITH US
HealthTech

HealthTech

AstraZeneca follows GSK with $1.5B annual savings push

Endpoints News logo

Published on

Add as a preferred source on Google
AstraZeneca follows GSK with $1.5B annual savings push

Bat­tered by late-stage tri­al fail­ures and de­ter­mined to meet its am­bi­tious $80 bil­lion-by-2030 rev­enue goal, As­traZeneca is cut­ting costs.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Cit­ing 'safe­ty' and 'free­dom,' HHS will al­low com­pound­ing of cer­tain well­ness pep­tides October 28, 2026

Ex­cite­ment, anx­i­ety run­ning high for Bio­gen's piv­otal tri­als dur­ing an­a­lyst call October 28, 2026

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion

Up­dat­ed: Lil­ly beats rev­enue fore­casts, lift­ing full-year out­look for third straight quar­ter

R&D chief Dean Li says Mer­ck out­flanked ri­vals with its sac-TMT can­cer pro­gram



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.